Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in china: current immunization strategy effectively prevented its sustained transmission.
In China, 5 patients with acute flaccid paralysis (AFP) associated with type 2 vaccine-derived poliovirus (VDPV) were identified by an AFP surveillance system from 1996 through 2009. A maximum-likelihood tree shows that all 5 Chinese VDPVs were independent. These 5 VDPVs were 100-216 d old according to the number of synonymous substitutions per synonymous site and 176-292 d old according to the number of substitutions per site. This result indicates limited virus replication since the administration of the initiating oral polio vaccine (OPV) dose, which is consistent with the rapid evolution rate of poliovirus genomes. The above-mentioned VDPVs have important implications in the global polio eradication initiative. Localized, limited, and transient circulation may be typical of OPVs; hence, independent VDPVs could be found because of the large population and excellent surveillance system, which permitted early detection and response, but sustained transmission was limited because of high population immunity.
World Health Organization Western Pacific Regional Polio Reference Laboratory and State Key Laboratory for Molecular Virology and Genetic Engineering, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing.
Yong
Y
Zhang
Dongmei
D
Yan
Shuangli
S
Zhu
Ning
N
Wen
Li
L
Li
Haiyan
H
Wang
Jianfeng
J
Liu
Xufang
X
Ye
Zhengrong
Z
Ding
Dongyan
D
Wang
Hui
H
Zhu
Li
L
Chen
Xiaohui
X
Hou
Hongqiu
H
An
Xiaofeng
X
Liang
Huiming
H
Luo
Olen
O
Kew
Wenbo
W
Xu
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D016000:Cluster Analysis; D005260:Female; D006801:Humans; D007114:Immunization / Q000379:methods*; D007223:Infant; D008297:Male; D017720:Molecular Epidemiology; D008969:Molecular Sequence Data; D010802:Phylogeny; D017354:Point Mutation; D011051:Poliomyelitis / Q000453:epidemiology* / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D017955:Poliovirus / Q000145:classification* / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects* / Q000276:immunology*; D015995:Prevalence; D012367:RNA, Viral / Q000235:genetics; D017422:Sequence Analysis, DNA; D017385:Sequence Homology
D011055:Poliovirus Vaccine, Oral; D012367:RNA, Viral